What question did this study set out to answer?

April 21, 2026Open Access

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

SSSurbhi SidanaPalo Alto University SNSaurabh P. NagarJohnson & Johnson (United States)SGSabyasachi GhoshJohnson & Johnson (United States)

Key Points

To describe non-ICANS neurologic events in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.
Analyzed data from two large US databases
Compared rates of neurologic events post-infusion to prior trials
Assessed real-world treatment outcomes
Rates of non-ICANS neurologic events were comparable or lower than previous trials
Supports the favorable risk-benefit profile of ciltacabtagene autoleucel for routine use

Abstract

In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk-benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article.

AI से पूछें

Bookmark

View Full Paper